Sana Biotechnology Appoints Brian Piper CFO to Steer SC451, SG293 Milestones with $133M Equity Backing
On Feb. 17 Sana Biotechnology named Brian Piper CFO, tapping his 25 years of biopharma experience including CFO tenures at Scorpion and Antares. Piper will allocate capital to advance SC451 islet cell and SG293 CAR T data readouts due in 12–18 months, backed by a $133M equity raise.
1. CFO Appointment
On Feb. 17 Sana Biotechnology promoted Brian Piper to Executive Vice President and Chief Financial Officer. Piper brings over 25 years in biopharmaceutical finance, including CFO roles at Scorpion Therapeutics and Antares Therapeutics.
2. Pipeline Milestones
Under Piper’s financial leadership, the company aims to deliver initial clinical data for its SC451 hypoimmune islet cell therapy and SG293 in vivo CAR T therapy within the next 12–18 months, key value inflection points for its cell engineering platforms.
3. Financing and Cash Runway
Late 2025 equity financing raised approximately $133 million, extending Sana’s cash runway into late 2026 and providing funding for ongoing development of its in vivo and ex vivo cell therapy pipeline.
4. CFO Mandate
Piper will focus on disciplined capital allocation, maintaining a strong balance sheet and optimizing funding strategies to support the advancement of Sana’s proprietary cell therapy programs.